Ascletis Pharma issues IPO, GIC set to invest $75mn

Ascletis Pharma, a Chinese biotech, will be the first company of its kind to file for an IPO in Hong Kong, which is set to be worth up to $457mn.

The company has secured commitment to invest from Singapore’s sovereign wealth fund, GIC (Government of Singapore Investment Corporation), which will be a cornerstone investor. GIC will contribute $75mn to the IPO, purchasing 20% of Ascletis’ shares, and will not be able to sell this stake for at least six months.

See also:

Cyberdyne sets up $82mn fund for cybernic healthcare technology

Feature: Global healthcare insurer Aetna is set to grow in Asia

Read the latest Asia edition of Business Chief

Altogether, a total of 224.1mn shares are being offered which will be worth between $1.53 and $2.04 each, putting the final figure of the IPO at between $343mn and $457mn.

Post flotation, the pharmaceutical firm is set to be valued at over $2bn, according to the South China Morning Post.

Proceeds will be spent on funding clinical trials, research and development of a new pipeline of drugs, and commercialisation of the drugs Danoprevir and Ravidasvir.

Danoprevir is the first cure for hepatitis C to have been developed by a Chinese company.


Featured Videos

View all

Schneider Electric - Global Specialist in Energy Management

Digital Strategy

Allianz Malaysia: Closer to customers through digital